209 related articles for article (PubMed ID: 33690844)
1. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies.
Gurnari C; Pagliuca S; Durkin L; Terkawi L; Awada H; Kongkiatkamon S; Zawit M; Hsi ED; Carraway HE; Rogers HJ; Visconte V; Maciejewski JP
Blood; 2021 Jul; 137(26):3685-3689. PubMed ID: 33690844
[TBL] [Abstract][Full Text] [Related]
2. VEXAS syndrome.
Grayson PC; Patel BA; Young NS
Blood; 2021 Jul; 137(26):3591-3594. PubMed ID: 33971000
[TBL] [Abstract][Full Text] [Related]
3. VEXAS: a vivid new syndrome associated with vacuoles in various hematopoietic cells.
Lytle A; Bagg A
Blood; 2021 Jul; 137(26):3690. PubMed ID: 34196684
[No Abstract] [Full Text] [Related]
4. Characteristic vacuolization of myeloid precursors and UBA1 mutation in a woman with monosomy X.
Luquet I; El Kassir A; Sailler L; Largeaud L; Mansat-De Mas V
Int J Lab Hematol; 2022 Feb; 44(1):29-30. PubMed ID: 34111334
[No Abstract] [Full Text] [Related]
5. Vacuolization in Myeloid and Erythroid Precursors in a Child with Menkes Disease.
Sayın S; Ünal Ş; Çetin M; Gümrük F
Turk J Haematol; 2019 Aug; 36(3):203-204. PubMed ID: 29716882
[No Abstract] [Full Text] [Related]
6. Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold.
Lacombe V; Prevost M; Bouvier A; Thépot S; Chabrun F; Kosmider O; Lacout C; Beucher A; Lavigne C; Geneviève F; Urbanski G
Br J Haematol; 2021 Oct; 195(2):286-289. PubMed ID: 34340250
[No Abstract] [Full Text] [Related]
7. A case of VEXAS syndrome with subtle morphologic findings.
Horton RK; Zheng G
Blood; 2021 Oct; 138(15):1378. PubMed ID: 34647982
[No Abstract] [Full Text] [Related]
8. Constant detection of cyclooxygenase 2 in terminal stages of myeloid maturation.
Tripodo C; Florena AM; Porcasi R; Ingrao S; Guarnotta C; Franco V
Acta Haematol; 2007; 117(1):48-50. PubMed ID: 17095859
[No Abstract] [Full Text] [Related]
9. Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Bourbon E; Heiblig M; Gerfaud Valentin M; Barba T; Durel CA; Lega JC; Barraco F; Sève P; Jamilloux Y; Sujobert P
Blood; 2021 Jul; 137(26):3682-3684. PubMed ID: 33619558
[No Abstract] [Full Text] [Related]
10. VEXAS syndrome in a woman.
Barba T; Jamilloux Y; Durel CA; Bourbon E; Mestrallet F; Sujobert P; Hot A
Rheumatology (Oxford); 2021 Nov; 60(11):e402-e403. PubMed ID: 33930131
[No Abstract] [Full Text] [Related]
11. Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.
Miller KP; Venkataraman G; Gocke CD; Batista DA; Borowitz MJ; Burns KH; Pratz K; Duffield AS
Am J Clin Pathol; 2019 Oct; 152(5):675-685. PubMed ID: 31305869
[TBL] [Abstract][Full Text] [Related]
12. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
Li P; Venkatachalam S; Ospina Cordona D; Wilson L; Kovacsovics T; Moser KA; Miles RR; Beck DB; George T; Tantravahi SK
Blood Adv; 2022 Jan; 6(2):405-409. PubMed ID: 34649277
[TBL] [Abstract][Full Text] [Related]
13. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series.
Koster MJ; Kourelis T; Reichard KK; Kermani TA; Beck DB; Cardona DO; Samec MJ; Mangaonkar AA; Begna KH; Hook CC; Oliveira JL; Nasr SH; Tiong BK; Patnaik MM; Burke MM; Michet CJ; Warrington KJ
Mayo Clin Proc; 2021 Oct; 96(10):2653-2659. PubMed ID: 34489099
[TBL] [Abstract][Full Text] [Related]
14. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
15. Aging-associated decrease in the histone acetyltransferase KAT6B is linked to altered hematopoietic stem cell differentiation.
Khokhar ES; Borikar S; Eudy E; Stearns T; Young K; Trowbridge JJ
Exp Hematol; 2020 Feb; 82():43-52.e4. PubMed ID: 32014431
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
17. Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis.
Yang L; Wang L; Kalfa TA; Cancelas JA; Shang X; Pushkaran S; Mo J; Williams DA; Zheng Y
Blood; 2007 Dec; 110(12):3853-61. PubMed ID: 17702896
[TBL] [Abstract][Full Text] [Related]
18. Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome.
Rieu JB; El Kassir A; Largeaud L; Dion J; Comont T; Mansat-De Mas V
Br J Haematol; 2021 Jul; 194(1):8. PubMed ID: 33651376
[No Abstract] [Full Text] [Related]
19. α-Hemoglobin-stabilizing Protein: An Effective Marker for Erythroid Precursors in Bone Marrow Biopsy Specimens.
Yu H; Pinkus JL; Pinkus GS
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):51-6. PubMed ID: 25611244
[TBL] [Abstract][Full Text] [Related]
20. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
